Hangzhou Bio-Sincerity Pharma-Tech Co (301096) Fair Value & Analysis

Healthcare · CN · Market cap 6.0B CNY

Below-average quality, and screening another 71% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥17.40). The favourable scenario is already priced in.
• Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (¥8.95 to ¥17.40) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.

How to read this chart

56‑month range ¥31.87 – ¥98.58 · fair‑value band ¥8.95 – ¥17.40 · the ¥44.68 price screens above the ¥13.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 24, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Hangzhou Bio-Sincerity Pharma-Tech Co (301096) currently trades at ¥44.68, while our model-based Fair Value estimate is ¥13.18, implying the stock looks roughly 70.5% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Hangzhou Bio-Sincerity Pharma-Tech Co generated revenue of 710M CNY at a net margin of -7.2%. Revenue grew 24.6% year over year. It earns a return on equity of -2.0%. Net debt stands at 408M CNY. Fundamentals as of Jul 24, 2026

Our scenario range runs from ¥8.95 (bear case) to ¥17.40 (bull case); at ¥44.68, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -71%, 301096 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (¥17.85) versus Asset-Based (¥15.27). Highest evidence: EV/EBITDA (54).

Key figures & financial health

Quality Score breakdown

About the company

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China.

Full company description

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business covers the principal links of drug discovery, pharmaceutical research, clinical trials, customized research and development and production, and registration applications. The company was incorporated in 2011 and is headquartered in Hangzhou, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Hangzhou Bio-Sincerity Pharma-Tech Co reported revenue of ¥678M in FY2025 versus ¥374M in FY2021, a compound +16.0%/yr. Reported net income was −¥90.4M in FY2025.

301096 screens 71% overvalued. Compare with Eli Lilly and Company →

Peer Group

Drug Manufacturers - General · 76 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.